RT Journal Article
SR Electronic
A1 Kuznar, Wayne
T1 RAM Fails to Improve OS as Second-Line Treatment for Hepatocellular Cancer
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 36
SP 18
OP 20
DO 10.1177/155989771436015
UL http://mdc.sagepub.com/content/14/36/18.2.abstract
AB As second-line therapy for hepatocellular carcinoma, ramucirumab did not improve overall survival compared with placebo in a phase 3 randomized study, but benefit was observed in a selected population with an elevated baseline level of alpha-fetoprotein. The results of the randomized, phase 3 Ramucirumab Second-Line Treatment in Patients With Hepatocellular Carcinoma After First-Line Therapy With Sorafenib study [REACH; NCT01140347] are discussed in this article.